Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells. - Wikidata - wikimedia - TriplyDB

Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells.

Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells.

http://www.wikidata.org/entity/Q37015742

about

Platinum-containing compound platinum pyrithione suppresses ovarian tumor proliferation through proteasome inhibition Proteasome Inhibitor YSY01A Abrogates Constitutive STAT3 Signaling via Down-regulation of Gp130 and JAK2 in Human A549 Lung Cancer Cells.Nitric Oxide Generated by Tumor-Associated Macrophages Is Responsible for Cancer Resistance to Cisplatin and Correlated With Syntaxin 4 and Acid Sphingomyelinase Inhibition.

P2860

Q33801982-AA9F8834-C58A-40EE-9CE4-C03670EABC0A Q41543982-7B8FD7EB-F033-4319-A80C-BF4377878D52 Q55262573-917477B4-7630-4D94-8D9D-B65BDF7F687E

P2860

Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells.

http://www.wikidata.org/entity/Q37015742

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Proteasome Inhibitor YSY01A En ...... nt Human Ovarian Cancer Cells.

@en

Proteasome Inhibitor YSY01A En ...... nt Human Ovarian Cancer Cells.

@nl

type

label

Proteasome Inhibitor YSY01A En ...... nt Human Ovarian Cancer Cells.

@en

Proteasome Inhibitor YSY01A En ...... nt Human Ovarian Cancer Cells.

@nl

prefLabel

Proteasome Inhibitor YSY01A En ...... nt Human Ovarian Cancer Cells.

@en

Proteasome Inhibitor YSY01A En ...... nt Human Ovarian Cancer Cells.

@nl

P1433

Q37015742-524344D3-A5F2-4DC9-B706-E087C5042328

P1476

Q37015742-1853384C-E8A2-4147-9A4B-8E1C4F911D9E

P2093

Q37015742-1B7B22A0-82BD-4196-8183-91A2F1AA7C28

Q37015742-2BF2E334-398D-4CF6-8A33-9995AD22DA62

Q37015742-874107D4-6CF2-4815-A6A7-158C7BD8C1D9

Q37015742-991F10BD-D9ED-489E-BC59-C049FF629D4A

Q37015742-9D3B8B43-9BB4-4877-97F8-5B02B5C80AD1

Q37015742-EB410943-4AD2-430D-B45B-2C2BC81AF753

Q37015742-EC920AFE-5DEE-4F3B-8BFE-7F9E0DCD0301

Q37015742-EFE56471-4990-40D9-9F2D-570E9077D99F

Q37015742-F2742031-605A-417E-8D30-737984F8F4A3

P2860

Q37015742-06FC76A5-CC44-49F4-9F3B-872CB074CF61

Q37015742-0C68D6F3-72F3-4803-8C2E-26EBD5F03A72

Q37015742-0FF312B7-4E39-4895-BD4D-3DE7A4DE729E

Q37015742-0FF5BEAE-DDE1-478B-8751-221E9FFB1F62

Q37015742-1390A341-7FAB-4D4E-9E79-9F1B2ADFBF1A

Q37015742-13B8D319-B51A-4841-BE38-289A192EB871

Q37015742-2083B105-E52A-4F63-B592-09ABDF3EB655

Q37015742-2C2EEEAE-9A8B-410D-8F04-3977A36899F2

Q37015742-2CEA36D9-1370-40DB-8A7A-93ACCFF51289

Q37015742-437C63DF-05E5-4CE2-9355-1D1B27BA0A1D

P304

Q37015742-381F5495-AFDA-4F5F-9B4F-D27A10F58E9F

P31

Q37015742-8E652CD1-E35C-4741-A86F-686054E2CE89

P356

Q37015742-99A08564-BCA0-4C3B-88E7-97CBA7A92174

P433

Q37015742-C80BFCD4-79C4-4B64-B2BD-4CBB96D24602

P478

Q37015742-0CDAD654-D46D-4F6F-BCB1-5EB539F9EE28

P577

Q37015742-85A88A46-2D15-4BF8-B461-D2D1B7146947

P698

Q37015742-61D2A477-333D-48A3-9653-8927BEF86C6B

P921

Q37015742-1648A174-ED09-4919-941A-F447BCD7E6A0

Q37015742-FC1C8D5C-E4EC-42B5-9220-6D40729881C8

P932

Q37015742-B4A7168E-54C4-4C4B-9A0E-4CB0594E5B5B

P356

P1433

Journal of Cancer

P1476

Proteasome Inhibitor YSY01A En ...... nt Human Ovarian Cancer Cells.

@en

P2093

Fu-Xiang Ran

http://www.w3.org/2001/XMLSchema#string

Guang-Liang Qiang

http://www.w3.org/2001/XMLSchema#string

Hua-Yu Yang

http://www.w3.org/2001/XMLSchema#string

Jing-Rong Cui

http://www.w3.org/2001/XMLSchema#string

Quan Zhou

http://www.w3.org/2001/XMLSchema#string

Run-Tao Li

http://www.w3.org/2001/XMLSchema#string

Wei Huang

http://www.w3.org/2001/XMLSchema#string

Xia Yuan

http://www.w3.org/2001/XMLSchema#string

Ze-Mei Ge

http://www.w3.org/2001/XMLSchema#string

P2860

NF- kappa B2/p100 induces Bcl-2 expression

Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa

Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer

Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.

An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma.

Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.

Proteasome inhibitor lactacystin enhances cisplatin cytotoxicity by increasing endoplasmic reticulum stress-associated apoptosis in HeLa cells.

Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.

YSY01A, a Novel Proteasome Inhibitor, Induces Cell Cycle Arrest on G2 Phase in MCF-7 Cells via ERα and PI3K/Akt Pathways.

Platinum resistance in breast and ovarian cancer cell lines

P304

1133-1141

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7150/JCA.14519

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27326257

http://www.w3.org/2001/XMLSchema#string

P921

P932

4911881

http://www.w3.org/2001/XMLSchema#string